Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet K Coller

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
British Journal of Clinical Pharmacology|December 18, 2003
Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicityJanet K Coller, Niels Krebsfaenger, Kathrin Klein, et al.
Cancer Chemotherapy and Pharmacology|August 12, 2022
Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicityJanine S Y Tam, Elise E Crame, Aurelia S Elz, et al.
Pharmacogenetics and Genomics|September 28, 2011
OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependenceJanet K Coller, Sharon Cahill, Carolyn Edmonds, et al.
Cancer Chemotherapy and Pharmacology|December 2, 2021
Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatmentKate R Secombe, Elise E Crame, Janine S Y Tam, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2013
The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitroYibai Li, Janet K Coller, Mark R Hutchinson, et al.
British Journal of Clinical Pharmacology|March 1, 2021
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipientsBenedetta C Sallustio, Benjamin D Noll, Rong Hu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 17, 2014
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot studyJanet K Coller, Imogen A White, Richard M Logan, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 26, 2006
Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatographyBenjamin J Davies, Megan K Herbert, Julie A Culbert, et al.
Therapeutic Drug Monitoring|November 23, 2011
Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samplesBenjamin D Noll, Janet K Coller, Andrew A Somogyi, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexilineBenjamin J L Davies, Janet K Coller, Heather M James, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
British Journal of Clinical Pharmacology|December 18, 2003
Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicityJanet K Coller, Niels Krebsfaenger, Kathrin Klein, et al.
Cancer Chemotherapy and Pharmacology|August 12, 2022
Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicityJanine S Y Tam, Elise E Crame, Aurelia S Elz, et al.
Pharmacogenetics and Genomics|September 28, 2011
OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependenceJanet K Coller, Sharon Cahill, Carolyn Edmonds, et al.
Cancer Chemotherapy and Pharmacology|December 2, 2021
Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatmentKate R Secombe, Elise E Crame, Janine S Y Tam, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2013
The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitroYibai Li, Janet K Coller, Mark R Hutchinson, et al.
British Journal of Clinical Pharmacology|March 1, 2021
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipientsBenedetta C Sallustio, Benjamin D Noll, Rong Hu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 17, 2014
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot studyJanet K Coller, Imogen A White, Richard M Logan, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 26, 2006
Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatographyBenjamin J Davies, Megan K Herbert, Julie A Culbert, et al.
Therapeutic Drug Monitoring|November 23, 2011
Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samplesBenjamin D Noll, Janet K Coller, Andrew A Somogyi, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexilineBenjamin J L Davies, Janet K Coller, Heather M James, et al.
Pageof 7